These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36028970)

  • 1. SGLT-2 Inhibitors and Nephroprotection in Patients with Diabetic and Non-diabetic Chronic Kidney Disease.
    Sarafidis P; Pella E; Kanbay M; Papagianni A
    Curr Med Chem; 2023; 30(18):2039-2060. PubMed ID: 36028970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun.
    Sarafidis P; Ortiz A; Ferro CJ; Halimi JM; Kreutz R; Mallamaci F; Mancia G; Wanner C;
    J Hypertens; 2021 Jun; 39(6):1090-1097. PubMed ID: 33443971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of SGLT-2 inhibitors in the treatment of chronic kidney disease : Clinical and practical implications.
    Säemann M; Cejka D; Schmaldienst S; Rosenkranz AR; Mayer G
    Wien Klin Wochenschr; 2023 Feb; 135(3-4):97-109. PubMed ID: 36251099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
    Mende CW
    Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: A systematic review and meta-analysis.
    Reyes-Farias CI; Reategui-Diaz M; Romani-Romani F; Prokop L
    PLoS One; 2023; 18(11):e0295059. PubMed ID: 38019892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, 'diabetic nephropathy', IgA nephropathy and podocytopathies with FSGS lesions.
    Anders HJ; Peired AJ; Romagnani P
    Nephrol Dial Transplant; 2022 Aug; 37(9):1609-1615. PubMed ID: 33313878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.
    Piperidou A; Loutradis C; Sarafidis P
    J Hum Hypertens; 2021 Jan; 35(1):12-25. PubMed ID: 32778748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
    Sarafidis P; Ferro CJ; Morales E; Ortiz A; Malyszko J; Hojs R; Khazim K; Ekart R; Valdivielso J; Fouque D; London GM; Massy Z; Ruggenenti P; Porrini E; Wiecek A; Zoccali C; Mallamaci F; Hornum M
    Nephrol Dial Transplant; 2019 Feb; 34(2):208-230. PubMed ID: 30753708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antidiabetic SGLT-2 inhibitors prevent progression of chronic kidney disease].
    Heine GH
    Dtsch Med Wochenschr; 2020 Jun; 145(11):762-766. PubMed ID: 32492746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DAPA-CKD: Significant Victory for CKD with or without Diabetes.
    Patel AB; Mistry K; Verma A
    Trends Endocrinol Metab; 2021 Jun; 32(6):335-337. PubMed ID: 33676827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease.
    Del Vecchio L; Beretta A; Jovane C; Peiti S; Genovesi S
    Drugs; 2021 Sep; 81(13):1491-1511. PubMed ID: 34363606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
    Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 17. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of SGLT-2 Inhibitors to Treat Chronic Kidney Disease in Primary Care.
    Bakris G
    J Fam Pract; 2022 Jul; 71(6 Suppl):S88-S93. PubMed ID: 35960952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
    Khoo CM; Deerochanawong C; Chan SP; Matawaran B; Sheu WH; Chan J; Mithal A; Luk A; Suastika K; Yoon KH; Ji L; Man NH; Pollock C
    Diabetes Obes Metab; 2021 Feb; 23(2):299-317. PubMed ID: 33155749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
    Weir MR; McCullough PA; Buse JB; Anderson J
    Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.